TUC3PII-01_TU2670 Phase IIa Clinical Study

Summary

This Protocol for TU2670 is to investigate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of TU2670 in subjects with moderate to severe endometriosis-associated pain.

Timeline

Start

2021-08-19

Primary completion

2024-01-23

Completion

2024-08-05

Drugs

Indications